2019
DOI: 10.2217/imt-2019-0008
|View full text |Cite
|
Sign up to set email alerts
|

Dupilumab in the Treatment of Asthma

Abstract: Dupilumab is a fully human monoclonal IgG4 antibody that blocks IL-4 and IL-13 signaling. Its efficacy has been assessed across a range of atopic diseases, due to its ability to inhibit T helper cell 2 (Th2) mediated inflammation. It has already been approved in the USA and Europe for the treatment of atopic dermatitis. Recently, it also gained approval in the USA as add-on treatment for moderate-to-severe asthma in adolescents and adults. Phase II and III randomized controlled trials have demonstrated improve… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0
5

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(13 citation statements)
references
References 38 publications
0
8
0
5
Order By: Relevance
“…Importantly, these data suggest that Th2 inhibition (Barranco et al, 2017) might potentially offer protection against COVID-19 severe symptoms, provided that there are minimal effects on Th1. Our findings may help guide personalized medicine decisions, particularly in patients that are eligible to receive Th2 inhibitors such as those with asthma or other atopic conditions (Barranco et al, 2017;Grey and Katelaris, 2019;Guttman-Yassky et al, 2019). However, this can truly be validated through clinical trials and longitudinal studies.…”
Section: Discussionmentioning
confidence: 91%
“…Importantly, these data suggest that Th2 inhibition (Barranco et al, 2017) might potentially offer protection against COVID-19 severe symptoms, provided that there are minimal effects on Th1. Our findings may help guide personalized medicine decisions, particularly in patients that are eligible to receive Th2 inhibitors such as those with asthma or other atopic conditions (Barranco et al, 2017;Grey and Katelaris, 2019;Guttman-Yassky et al, 2019). However, this can truly be validated through clinical trials and longitudinal studies.…”
Section: Discussionmentioning
confidence: 91%
“…The use of dupillumab warrants more prospective studies in IgG4-RD. Dupilumab was also recently approved for treatment of moderate to severe asthma both in adolescents and adults (131). Kasaian et al created a recombinant bifunctional IL-4/IL-13 antagonist that in a mouse of model of asthma reduced not only IL-4-dependent increase in serum IgE levels but also IL-13dependent airway hyper-responsiveness and lung inflammation (132).…”
Section: Therapeutic Implications and Future Directionsmentioning
confidence: 99%
“…The use of dupillumab warrants more prospective studies in IgG4-RD. Dupilumab was also recently approved for treatment of moderate to severe asthma both in adolescents and adults ( 131 ).…”
Section: Therapeutic Implications and Future Directionsmentioning
confidence: 99%
“…Este inmunobiológico fue aprobado en 2018 por la FDA para su uso en pacientes mayores de 12 años con asma eosinofílica grave esteroide dependiente 4 . La eficacia de dupilumab ha sido comprobada en ensayos clínicos controlados, mostrando una disminución en las exacerbaciones de asma (que es mayor en sujetos con un recuento de eosinófilos mayor o igual a 300 células/microlitro y con FENO mayor o igual a 25 ppb), una mejoría en la función pulmonar con incremento del VEF1, disminución en la necesidad de esteroides orales en un 70 % (incluso con posibilidad de discontinuarlos) y una mejora en los puntajes clínicos del control de síntomas 17 . Debe ser administrado en dosis de 400 a 600 mg por vía subcutánea, seguido de 200 o 300 mg cada 2 semanas.…”
Section: Dupilumabunclassified
“…Los efectos adversos más frecuentes con su uso son reacciones en el sitio de la administración (en 18% de los pacientes) e hipereosinofilia (en 4 a 14% de los pacientes). La hipereosinofilia es transitoria y asintomática en la mayoría de los pacientes, aunque algunos presentan síntomas de neumonitis y miositis 17,18 .…”
Section: Dupilumabunclassified